1-(chloromethyl)-5-nitro-1,2-dihydro-3H-benzo[e]indole-7-sulfonamide | 885227-01-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(chloromethyl)-5-nitro-1,2-dihydro-3H-benzo[e]indole-7-sulfonamide
• 英文别名: 1-(chloromethyl)-5-nitro-2,3-dihydro-1H-benzo[e]indole-7-sulfonamide
• CAS: 885227-01-0
• 化学式: C₁₃H₁₂ClN₃O₄S
• 分子量: 341.775
• InChiKey: YNNWMZLQWYMTSM-UHFFFAOYSA-N

物化性质

• 熔点：
  183-187 °C (decomp)(Solv: ethyl acetate (141-78-6))
• 沸点：
  594.9±60.0 °C(Predicted)
• 密度：
  1.540±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(chloromethyl)-5-nitro-1,2-dihydro-3H-benzo[e]indole-7-sulfonamide 、 异阿魏酸 在 对甲苯磺酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 碳酸氢钠 作用下， 以 异丁酰胺 、 水 、 2,4-滴二甲胺盐 为溶剂， 反应 22.0h， 以82%的产率得到1-(chloromethyl)-3-[(2E)-3-(3-hydroxy-4-methoxyphenyl)-2-propenoyl]-5-nitro-1,2-dihydro-3H-benzo[e]indole-7-sulfonamide
  参考文献：
  名称：

  体内低氧性肿瘤细胞的选择性治疗：磷酸双氮多卡霉素的前药。

  摘要：

  达到缺氧目标：将硝基前药与水溶性磷酸酯结合使用，可以将杜卡霉素类似物从剧毒的DNA烷基化剂转化为高度选择性的抗肿瘤化合物。这些前药（参见方案）在体内对缺氧肿瘤细胞具有出色的活性，这些细胞通常被认为对常规疗法最有抵抗力。

  DOI：

  10.1002/anie.201004456
• 作为产物：
  描述：

  1-(chloromethyl)-5-nitro-3-(trifluoroacetyl)-1,2-dihydro-3H-benzo[e]indole-7-sulfonyl chloride 在 氨 、 caesium carbonate 作用下， 以 四氢呋喃 、 水 、 甲醇 为溶剂， 反应 0.37h， 以96%的产率得到1-(chloromethyl)-5-nitro-1,2-dihydro-3H-benzo[e]indole-7-sulfonamide
  参考文献：
  名称：

  WO2006/43839

  摘要：

  公开号：

文献信息

• BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY
  申请人：Szekely Zoltan

  公开号：US20090118349A1

  公开（公告）日：2009-05-07

  The present invention relates to (i) conjugates comprising two DNA alkylating subunits linked by a moiety fitting to the minor groove of the DNA, (ii) to their preparation and (iii) to their use in cancer therapy. The alkylating subunits are especially cytotoxic under hypoxic conditions found in cancer cells. The compounds of the present invention and compositions thereof are useful in the treatment of cancer in a mammal, both alone or in a combination with other anti-cancer agents (e.g. checkpoint abrogators) and/or radiation. They may also be used as cytotoxic units for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT). The present invention provides the compounds of Formula (I), Formula (II) and Formula (III): for treating cancer in a mammal.

  本发明涉及（i）由适合于DNA小沟的基团连接的两个DNA烷基化亚基组成的共轭物，（ii）它们的制备和（iii）它们在癌症治疗中的应用。烷基化亚基在癌细胞中发现的低氧条件下特别具有细胞毒性。本发明的化合物及其组合物在哺乳动物中治疗癌症方面具有用途，可以单独使用或与其他抗癌药物（例如检查点阻断剂）和/或放射线结合使用。它们还可以用作基因定向酶-前药疗法（GDEPT）和抗体定向酶-前药疗法（ADEPT）的细胞毒性单位。本发明提供了式（I）、式（II）和式（III）的化合物，用于哺乳动物中治疗癌症。
• Nitrobenzindoles and Their use in Cancer Therapy
  申请人：Denny William Alexander

  公开号：US20080119442A1

  公开（公告）日：2008-05-22

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及其作为低氧选择性药物和放射增敏剂在癌症治疗中的使用，可以单独使用或与辐射和/或其他抗癌药物联合使用。
• Nitrobenzindoles and their use in cancer therapy
  申请人：Auckland Uniservices Limited

  公开号：US07718688B2

  公开（公告）日：2010-05-18

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及它们作为治疗癌症的低氧选择性药物和放射增敏剂的用途，无论是单独使用还是与放射线和/或其他抗癌药物联合使用。
• Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitro <i>seco</i>-1,2,9,9a-Tetrahydrocyclopropa[<i>c</i>]benz[<i>e</i>]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents
  作者：Moana Tercel、Graham J. Atwell、Shangjin Yang、Ralph J. Stevenson、K. Jane Botting、Maruta Boyd、Eileen Smith、Robert F. Anderson、William A. Denny、William R. Wilson、Frederik B. Pruijn

  DOI：10.1021/jm901202b

  日期：2009.11.26

  Nitrochloromethylbenzindolines (nitroCBIs) are a new class of hypoxia-activated prodrugs for antitumor therapy. The recently reported prototypes undergo hypoxia-selective metabolism to form potent DNA minor groove alkylating agents and are selectively toxic to some but not all hypoxic tumor cell lines. Here we report a series of 31 analogues that bear an extra electron-withdrawing substituent that serves to raise the one-electron reduction potential of the nitroCBI. We identify a subset of compounds, those with a basic side chain and sulfonamide or carboxamide substituent, that have consistently high hypoxic selectivity. The best of these, with a 7-sulfonamide substituent, displays hypoxic cytotoxicity ratios of 275 and 330 in Skov3 and HT29 human tumor cell lines, respectively. This compound (28) is efficiently and selectively metabolized to the corresponding aminoCBI, is selectively cytotoxic tinder hypoxia in all 11 cell lines examined, and demonstrates activity against hypoxic tumor cells in a human tumor xenograft in vivo.
• US7718688B2
  申请人：——

  公开号：US7718688B2

  公开（公告）日：2010-05-18